The American Journal of Surgery
Volume 196, Issue 3 , Pages 326-332 , September 2008

Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer

  • Celestino Pio Lombardi, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Maurizio Bossola, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +011-390630154330; fax: +011-390630155941
    • ,
  • Pietro Princi, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Mauro Boscherini, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Giuseppe La Torre, M.D.

      Affiliations

    • Istituto di Igiene, Epidemiologia e Unità di Biostatistica, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Marco Raffaelli, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Emanuela Traini, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Massimo Salvatori, M.D.

      Affiliations

    • Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Alfredo Pontecorvi, M.D.

      Affiliations

    • Istituto di Patologia Speciale Medica, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Rocco Bellantone, M.D.

      Affiliations

    • Divisione di Chirurgia Endocrina, Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy

Received 3 August 2007 ,Revised 17 September 2007

References 

  1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306
  2. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463
  3. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J Clin Endocrinol Metab. 2002;87:1490–1498
  4. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888–896
  5. Ladenson PW. Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid. 1999;9:429–433
  6. Mazzaferri EL, Robbins J, Spencer CA, et al. A consensus report of the role of the serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  7. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem. 1996;42:164–173
  8. Spencer CA, Wang CC. Thyroglobulin measurement (techniques, clinical benefits, and pitfalls). Endocrinol Metab Clin North Am. 1995;24:841–863
  9. Rubello D, Casara D, Girelli ME, et al. Clinical meaning of circulating anti-thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med. 1992;33:1478–1480
  10. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121–1127
  11. Ditkoff BA, Marvin MR, Yemul S, et al. Detection of circulating thyroid cells in peripheral blood. Surgery. 1996;120:959–965
  12. Tallini G, Ghossein RA, Emanuel J, et al. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. J Clin Oncol. 1998;16:1158–1166
  13. Ringel MD, Ladenson PW, Levine MA. (1998) Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab. 1998;83:4435–4442
  14. Biscolla RP, Cerutti JM, Maciel RM. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. J Clin Endocrinol Metab. 2000;85:3623–3627
  15. Bugalho MJ, Domingues RS, Pinto AC, et al. Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol. 2001;145:409–413
  16. Bojunga J, Roddiger S, Stanisch M, et al. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. Br J Cancer. 2000;82:1650–1655
  17. Denizot A, Delfino C, Dutour-Meyer A, et al. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer. Thyroid. 2003;13:867–872
  18. Bellantone R, Lombardi CP, Bossola M, et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. Cancer. 2001;92:2273–2279
  19. Olsson CA, de Vries GM, Raffo AJ, et al. Preoperative reverse transcriptase polymerase chain reaction for prostatic specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996;155:1557–1562
  20. Ghossein R, Rosai J, Scher HI, et al. Prognostic significance of detection of prostate specific antigen transcripts in the peripheral blood of patients with metastatic androgen independent prostatic carcinoma. Urology. 1997;50:100–105
  21. Ghossein RA, Coit D, Brennan M, et al. Prognostic significance of peripheral blood and bone marrow tyrosinase mRNA in malignant melanoma. Clin Cancer Res. 1998;4:419–428
  22. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol. 1996;14:2091–2097
  23. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol. 1998;16:1760–1769
  24. Silva JM, Dominguez G, Silva J, et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res. 2001;7:2821–2825
  25. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002;20:3404–3412
  26. Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236:768–776
  27. Minata M, Nishida N, Komeda T, et al. Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:445–451
  28. Fraker DL, Skarulis M, Livolsi V. 1997 thyroid tumors. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997;p. 1269–1284
  29. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Taskforce. Thyroid. 2006;16:109–142
  30. Sobin CH, Witteking CH. TNM Classification of Malignant Tumor. In: 6th ed.. Hoboken, NJ: Wiley; 2002;p. 52–56
  31. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Nat Cancer Inst. 1999;91:1113–1124
  32. Elisei R, Vivaldi A, Agate L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2004;89:33–39
  33. Haber RS. The diagnosis of recurrent thyroid cancer—a new approach. J Clin Endocrinol Metab. 1998;83:4189–4190
  34. Chelly J, Concordet JP, Kaplan JC. Illegitimate transcription of any gene in any cell type. Proc Natl Acad Sci U S A. 1989;86:2617–2621
  35. Ringel MA, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin gene are reduced in papillary thyroid cancer. Mod Pathol. 2001;14:289–296
  36. Ohta K, Endo T, Onaya T. The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxydase in neoplastic human thyroid tissues. Biochem Biophys Res Comm. 1991;174:1148–1153
  37. Hoang-Vu C, Dralle H, Scheumann G, et al. Gene expression of differentiation and dedifferentiation markers in normal and malignant human thyroid tissues. Exp Clin Endocrinol. 1992;100:51–56
  38. Bertaux F, Noel M, Lasmoles F, et al. Identification of the exon structure and four alternative transcripts of the thyroglobulin-encoding gene. Gene. 1995;156:297–301
  39. Bertaux F, Noel M, Malthiery Y, et al. Demonstration of a heterogeneous transcription pattern of thyroglobulin mRNA in human thyroid tissue. Biochem Biophys Res Comm. 1991;178:586–592

PII: S0002-9610(08)00310-3

doi: 10.1016/j.amjsurg.2007.09.047

The American Journal of Surgery
Volume 196, Issue 3 , Pages 326-332 , September 2008

Article Tools

* Image Usage & Resolution